Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

摘要

Presented in part at the American Society of Clinical Oncology annual meeting, Chicago 31 May to 3 June 2014.